logo
logo

You're viewing 1 of thousands of funding rounds tracked monthly

Members receive AI-scored leads and instant alerts when companies matching their criteria raise capital. Search all rounds by stage, amount, and investor.

LUCA Science Announces $9.8 Million Series A Financing to Support Research and Development of Functional Mitochondria as Therapeutic Agents

LUCA Science Announces $9.8 Million Series A Financing to Support Research and Development of Functional Mitochondria as Therapeutic Agents

09/01/20, 2:38 PM
Money raised
$9 million
Round Type
series a
LUCA Science, a company developing functional mitochondria as therapeutic agents, an emerging platform to treat damaged tissues and organs, today announced the closing of a $9.8 million Series A financing. The funding round was led by Axil Capital Partners. Additional participating investors included Remiges Ventures, Nippon Venture Capital, Fast Track Initiative and CaHC.

Company Info

Company
Luca Science
Additional Info
Philippe Fauchet, OBE, Venture Partner at 4BIO Capital, said: “LUCA Science has all the right ingredients to be an international success: it has the science, international team, and fantastic support from experienced investors. LUCA Science will use its platform technology to manufacture, store and deliver innovative mitochondrial drugs to research and development of therapeutics for unmet medical needs in a wide range of diseases for which there have been no effective treatments. LUCA Science is a preclinical stage biopharmaceutical company pioneering a new class of mitochondrial therapy to restore cellular bioenergetics in dysfunctional or damaged tissues and organs.
Live intelligence

Get deeper insights on Luca Science

Direct contacts for 1 executives

AI alerts when similar companies raise funding

Track Luca Science's next moves

Used by teams at Oracle, Google, LinkedIn

Related people

LH

Sign up to get related executive contact information